Case Type: Mergers & Acquisitions

Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock.

Vector Group Ltd. (NYSE: VGR), relating to a proposed tender offer from JTI Holding, Inc. Under the terms of the agreement, JTI offers to acquire outstanding shares of Vector Group common stock for $15.00 in cash per share.

Terran Orbital Corporation (NYSE: LLAP), relating to its proposed merger with Lockheed Martin Corporation. Under the terms of the agreement, Terran common stock will be automatically converted into the right to receive $0.25 in cash per share.

Arch Resources, Inc. (NYSE: ARCH), relating to its proposed merger with Consol Energy, Inc. Under the terms of the agreement, all Arch Resources common stock will be automatically converted into the right to receive 1.326 shares of Consol Energy stock.

Kellanova (NYSE: K), relating to its proposed merger with Mars, Inc. Under the terms of the agreement, all Kellanova common stock will be automatically converted into the right to receive $83.50 in cash per share.

Fortune Rise Acquisition Corporation (Nasdaq: FRLA), relating to its proposed merger with Water On Demand, Inc. Under the terms of the agreement, all FRLA common stock will be converted into the right to receive shares of Water On Demand common stock.

Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.

Revance Therapeutics, Inc. (Nasdaq: RVNC), relating to its proposed merger with Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 in cash per share they own.

GSE Systems, Inc. (Nasdaq: GVP), relating to its proposed merger with Pelican Energy Partners. Under the terms of the agreement, GSE Systems shareholders will receive $4.10 in cash per share they own.

G1 Therapeutics, Inc. (Nasdaq: GTHX), relating to its proposed merger with Kahn Swick & Foti, LLC (“KSF”). Under the terms of the proposal, KSF will commence a tender offer to purchase GTHX stock at a price of $7.15 per share.